(5S)-3-methyl-5-phenyl-2-oxazolidinone | 913289-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (5S)-3-methyl-5-phenyl-2-oxazolidinone
• 英文别名: (S)-3-methyl-5-phenyloxazolidin-2-one；(5S)-3-methyl-5-phenyl-1,3-oxazolidin-2-one
• CAS: 913289-36-8
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: MTEQJQQIAAAKRU-SECBINFHSA-N

物化性质

• 熔点：
  72-74 °C
• 沸点：
  373.0±31.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5S)-3-methyl-5-phenyl-2-oxazolidinone 在 氢氧化钾 作用下， 以 水 为溶剂， 反应 3.0h， 以91%的产率得到N-甲基(S)-2-羟基-2-苯基乙胺
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017
• 作为产物：
  描述：

  (S)-(+)-2-氯-1-苯乙醇 在 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.25h， 生成 (5S)-3-methyl-5-phenyl-2-oxazolidinone
  参考文献：
  名称：

  Solvent and in situ catalyst preparation impacts upon Noyori reductions of aryl-chloromethyl ketones: application to syntheses of chiral 2-amino-1-aryl-ethanols

  摘要：

  As part of medicinal chemistry efforts we found it necessary to develop general syntheses of highly enantiomerically enriched 1-aryl-2-chloroethanols and 1-aryl-2-methylaminoethanols. A survey of literature methods suggested that a truly general approach had not yet been reported, encouraging us to undertake the development of such a methodology. This study describes the design, development, and reduction to practice of a general synthesis of chiral 1-aryl-2-chloroethanols and the transformation of these entities to highly enantiomerically enriched 1-aryl-2-methylaminoethanols. Of particular importance were observations of the impact of solvent and the method of catalyst preparation on the yield and enantiomerical excess of chlorohydrins prepared via Noyori transfer hydrogenations of aryl-chloromethyl ketones. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.017

文献信息

• Synthesis of chiral oxazolidinone derivatives through lipase-catalyzed kinetic resolution
  作者：Yan Zhang、Yang Zhang、Yansong Ren、Olof Ramström

  DOI：10.1016/j.molcatb.2015.08.004

  日期：2015.12

  The synthesis of enantioenriched oxazolidinone derivatives through lipase-catalyzed kinetic resolution is described. The synthesis comprised a two-step, cascade acylation in one pot, resulting in a range of oxazolidinone derivatives in good yields and excellent enantiopurities.

  描述了通过脂肪酶催化的动力学拆分合成对映体富集的恶唑烷酮衍生物。该合成在一锅中包括两步，级联酰化反应，从而产生了一系列具有良好收率和出色对映纯度的恶唑烷酮衍生物。
• CETP INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140221383A1

  公开（公告）日：2014-08-07

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括化合物的药物可接受盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化：在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，而5元环的另一个位置具有直接连接到环或通过-CH2-连接到环的芳基，杂环，环烷基，苯并杂环或苯并环烷基取代基。
• EP0415981A4
  申请人：——

  公开号：EP0415981A4

  公开（公告）日：1991-10-09
• RETROVIRAL PROTEASE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP0415981A1

  公开（公告）日：1991-03-13
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.